Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth.
Revenue for the quarter ended June 30 was $48.1 mill
DoorDash (NASDAQ:DASH) executives said the company’s Q2 2026 performance reflected continued growth in restaurant delivery, grocery and retail, international operations and subscription adoption, while improved unit economics supported profitability and ongoing investment in technology.
During the
Chime Financial (NASDAQ:CHYM) reported second-quarter results that showed accelerating member, revenue and transaction-profit growth, while the company raised its full-year outlook and outlined new product initiatives aimed at higher-income consumers.
Active members grew 20% year over year to 10.4
Clearfield (NASDAQ:CLFD) reported fiscal third-quarter 2026 net sales of $43.9 million, up 13% from $38.8 million a year earlier and 28% sequentially, as the company advanced its push into data center connectivity while confronting continued delays in broadband-network deployment.
Net income from c
Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures.
Chief Executive Officer Andrew Toy said the company views its Clove
Cirrus Logic (NASDAQ:CRUS) reported record fiscal first-quarter revenue of $460 million for the June quarter, up 2% sequentially and 13% from a year earlier, driven by higher component sales into smartphones. The company posted GAAP earnings per share of $1.47 and non-GAAP earnings per share of $1.8
Central Garden & Pet (NASDAQ:CENT) reported an 8% decline in fiscal third-quarter net sales to $882 million, primarily reflecting its exit from the pet distribution business at the beginning of the quarter. Excluding that business, organic net sales rose 2% to $862 million, supported by growth in bo
Coherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise.
Chief Executive Officer Denny Lanfear said
Carlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes.
Chairman and Chief Executive Officer Mike Cordonnier said the
Morin exercised options at $8.19 and liquidated immediately under a pre-established Rule 10b5-1 trading plan, retaining 20,157 direct shares and 76,194 derivative securities.
Rivian's investor focus is largely on the R2 launch and ramp-up, but don't overlook its staggering margins in software and services that are helping offset early R2 launch costs.
Voice AI technology company SoundHound AI (NASDAQ:SOUN) announced better-than-expected revenue in Q2 CY2026, with sales up 45% year on year to $61.9 million....
Aerospace and defense company Redwire (NYSE:RDW) announced better-than-expected revenue in Q2 CY2026, with sales up 89.6% year on year to $117.1 million. The...
Offshore drilling contractor Transocean (NYSE:RIG) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 2.2% year on yea...
Online travel agency Expedia (NASDAQ:EXPE) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 14% year on year to $4.32 bill...
Bumble (NASDAQ:BMBL) reported second-quarter results that were in line with its expectations, with revenue landing in the upper half of its guidance range and adjusted EBITDA exceeding the high end, as the dating-app company continued a technology and product transformation.
Founder and CEO Whitney
biote (NASDAQ:BTMD) reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half
Beyond Meat (NASDAQ:BYND) reported second-quarter 2026 revenue above its guidance range as international retail growth partially offset continued weakness in U.S. channels and international food service. Management said the company is pursuing a turnaround centered on expanding in Europe and Canada,
Caris Life Sciences (NASDAQ:CAI) reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization.
The com
